Key positives include a strongly differentiated technology platform in a large and underpenetrated market, improving gross margins that suggest solid underlying product economics, and a history of raising capital to support growth. The balance sheet still shows positive equity and adequate liquidity, and the company has built a meaningful base of intellectual property and clinical evidence. Its ability to treat patient groups that are underserved by existing hypoglossal nerve stimulation therapies gives it a strategic foothold that could translate into durable demand if commercial execution is effective.

The main concerns are financial and execution‑related. Net losses and cash burn are large and have been widening, with operating and free cash flows deeply negative. Cash reserves, while still adequate in the near term, have fallen substantially since the peak IPO years, and debt has increased, raising the importance of future capital access. Commercial traction, particularly in the U.S., is not yet proven at scale, and the company must displace or coexist with a strong incumbent while managing reimbursement, physician education, and legal disputes around patents. If revenue growth does not accelerate meaningfully or costs are not contained, ongoing dilution or higher leverage could become necessary.

Nyxoah’s outlook is highly leveraged to two dynamics: clinical and commercial success of Genio, especially in the U.S. and among patients with complete concentric collapse, and the company’s ability to gradually narrow its losses as revenue scales. If it can translate its technological advantages and expanding clinical data into broader adoption and reimbursement, the business could move toward a more sustainable footing over time. Conversely, if adoption is slower than expected or competitive and reimbursement pressures intensify, the combination of high cash burn and a weakening balance sheet could become more problematic. Overall, this remains an early‑stage, high‑potential but high‑uncertainty story in med‑tech, where innovation strength is clear but financial sustainability is not yet established.